Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide + Steroids for Acute GVHD After Stem Cell Transplant
NCT05443425Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jun 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of leflunomide in Acute Graft-Versus-Host Disease (aGvHD), sponsored by City of Hope. Primary endpoint: Incidence of adverse events at 6 months. Started Jun 2023; status: recruiting.
02
Drugs
leflunomide
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05443425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05443425.